Reunion Neuroscience (NASDAQ:REUN) Lowered to Hold at Stifel Nicolaus

Reunion Neuroscience (NASDAQ:REUN – Get Rating) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Wednesday, The Fly reports.

REUN has been the subject of a number of other reports. EF Hutton Acquisition Co. I restated a “buy” rating and issued a $11.00 price objective on shares of Reunion Neuroscience in a report on Tuesday, February 14th. Bloom Burton reiterated a “buy” rating on shares of Reunion Neuroscience in a research note on Monday, November 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Reunion Neuroscience in a research note on Wednesday, February 15th.

Reunion Neuroscience Stock Performance

Shares of NASDAQ REUN opened at $0.86 on Wednesday. Reunion Neuroscience has a twelve month low of $0.76 and a twelve month high of $8.70. The company has a 50 day moving average of $1.19 and a 200 day moving average of $1.55.

Reunion Neuroscience (NASDAQ:REUN – Get Rating) last announced its quarterly earnings data on Tuesday, February 14th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.10). On average, sell-side analysts forecast that Reunion Neuroscience will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Reunion Neuroscience

Hedge funds have recently modified their holdings of the business. Cidel Asset Management Inc. bought a new position in Reunion Neuroscience in the 3rd quarter worth $29,000. Jane Street Group LLC bought a new position in Reunion Neuroscience in the 3rd quarter worth $51,000. Finally, One Plus One Wealth Management LLC bought a new position in shares of Reunion Neuroscience during the 3rd quarter valued at about $109,000. Institutional investors own 12.88% of the company’s stock.

About Reunion Neuroscience

(Get Rating)

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.